Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
70
resultados
Última actualización
29/09/2025 [07:25:00]
Resumen de: US2025298039A1
This disclosure relates to methods for diagnosing and treating a tauopathy, e.g., Alzheimer's disease, in a subject, the methods comprising, in part, identifying one or more post-translation modifications (PTMs) in the subject.
Resumen de: US2025296997A1
The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
Resumen de: WO2025199495A1
The present invention provides methods and compositions for reducing internalization and/or trafficking of tan in neuronal cells comprising contacting the cells with an effective amount of VLDL receptor antagonist. The invention further provides a method of treating or preventing Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of a VLDL receptor antagonist.
Resumen de: US2025295643A1
In various aspects and embodiments the invention provides a method of treating epilepsy in a subject in need thereof, the method comprising providing to the subject an effective amount of an FLNA modulator. In various embodiments, the FLNA modulator is PTI-125 or kartogenin. In various embodiments, the epilepsy is epilepsy associated with focal cortical dysplasia (FCD) type II or tuberous sclerosis complex (TSC).
Resumen de: AU2025226709A1
The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody. The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody. ep e p h e p r e s e n t i n v e n t i o n r e l a t e s t o a n a n t i - a l p h a - s y n u c l e i n a n t i b o d y p r e f e r e n t i a l l y r e c o g n i z i n g a l p h a - s y n u c l e i n a g g r e g a t e s a n d a u s e o f d e t e c t i o n , d i a g n o s i s , a n d o r t r e a t m e n t o r p r e v e n t i o n o f v a r i o u s d i s e a s e s c a u s e d b y a c c u m u l a t i o n o f a l p h a - s y n u c l e i n a g g r e g a t e s , o r t h e i r r e l a t e d s y m p t o m d i s e a s e s b y u s i n g t h e a n t i - a l p h a - s y n u c l e i n a n t i b o d y
Resumen de: AU2025226659A1
The present disclosure provides methods for blood-based examination useful to identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein. The present disclosure provides methods for blood-based examination useful to identify subjects with Aß amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aß amyloidosis, as well as methods for treating subjects diagnosed with Aß amyloidosis by the methods disclosed herein. ep h e p r e s e n t d i s c l o s u r e p r o v i d e s m e t h o d s f o r b l o o d - b a s e d e x a m i n a t i o n u s e f u l t o e p i d e n t i f y s u b j e c t s w i t h ß a m y l o i d o s i s a n d o r t o i d e n t i f y s u b j e c t s w h o s h o u l d o r s h o u l d n o t u n d e r g o f u r t h e r t e s t i n g o r t r e a t m e n t f o r ß a m y l o i d o s i s , a s w e l l a s m e t h o d s f o r t r e a t i n g s u b j e c t s d i a g n o s e d w i t h ß a m y l o i d o s i s b y t h e m e t h o d s d i s c l o s e d h e r e i n
Resumen de: US2025298023A1
A method for diagnosing neurodegenerative diseases, the method including measuring the JNK3 levels in a biological sample selected from plasma, CSF, and saliva. The method also includes measuring P-JNK3.
Resumen de: WO2025199015A1
This invention provides skin cell fibroblast- and blood-based methods for determining whether a human subject has a gene expression profile characteristic of AD. This invention also provides related methods for determining whether a demented human subject is afflicted with AD or non-ADD, and for determining whether a non-demented human subject has an increased likelihood of becoming afflicted with AD.
Resumen de: WO2025199451A2
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive or quality-of-life function.
Resumen de: WO2024107948A1
A process for determining an extent of a central nervous system (CNS) specific neurological condition in a subject including collecting a biological sample of biofluid from the subject and measuring a quantity of a first biomarker, or metabolite of or mRNA corresponding to, the first biomarker from the sample from a dried spot or through a microfluidic device. The biofluid is capillary blood or saliva, which affords ease of collection advantages that are attractive for field-, hospital-, and home-based environments. The process being useful in the diagnosis, care, and management of brain specific abnormal neurological conditions in general, and in particular, to traumatic brain injury (TBI) and (TBI-induced) Alzheimer's disease (AD) and Alexander disease, in which a GFAP mutation is implicated in white matter deterioration.
Resumen de: US2025277799A1
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Resumen de: US2025289874A1
The present application belongs to the technical field of biomedicine, and more particularly, relates to an antibody or an antigen-binding fragment thereof capable of specifically binding to p-tau 217, and a multi-specific molecule, a pharmaceutical composition, and a kit comprising same. The present application further relates to use of the antibody or antigen-binding fragment thereof in preparing a kit or a drug. A monoclonal antibody (for example, 2A7 antibody) according to the present application has a high clinical application value in the detection and prevention of AD and the treatment of AD and other tau protein diseases.
Resumen de: US2025290037A1
Modified cells that express and present or secrete at least one therapeutic molecule that can treat or ameliorate a disease of interest such as but not limited to Alzheimer's disease. In the modified cells, expression of the therapeutic molecule is induced when the modified cells are proximate to or in contact with pathology related to the disease of interest. The present disclosure also relates to compositions and kits comprising the disclosed cells. The present disclosure also relates to methods of using the disclosed cells for treating disease.
Resumen de: WO2025192800A1
The present invention relates to a pharmaceutical composition for preventing or treating Alzheimer's disease, the composition comprising, as an active ingredient, neural crest-derived nasal turbinate stem cells (NTSCs) expressing SSEA3 and CD105. Treatment with the NTSCs expressing SSEA3 and CD105 or with an NTSC cell line including at least a predetermined proportion of the NTSCs was found to result in remarkably good therapeutic activity against Alzheimer's disease. Therefore, the present invention is expected to be effectively used not only as a composition for preventing or treating Alzheimer's disease in which the composition includes, as an active ingredient, NTSCs expressing SSEA3 and CD105 or an NTSC cell line including at least a predetermined proportion of the NTSCs, but also for uses such as screening of NTSC formulations that can be used to treat Alzheimer's disease, or prediction of the therapeutic efficacy thereof.
Resumen de: US2025290935A1
Provided in the present application is a marker of Alzheimer's disease, which marker comprises monocyte chemoattractant protein-1 (MCP 1). Further provided in the present application are a method for detecting the marker of Alzheimer's disease, a kit for detecting Alzheimer's disease, and the use of the marker, the detection method and the kit in the screening of a drug for treating Alzheimer's disease.
Resumen de: WO2025190329A1
Anti-Aβ drug screening targets and a drug screening method. The screening method uses different Aβ aggregates prepared by simulating the in vivo environment and conditions as targets, to more accurately and effectively screen anti-Aβ candidate drugs; the Aβ targets involved in the screening method are aggregated and incubated under conditions approaching different in vivo microenvironments, and do not require labeling or modification; in addition, the screened drug molecules do not require any modification or labeling, and are not limited to any specific drug class, being widely applicable to different drug types, such as antibodies, peptides and small molecules, truly reflecting the interactions between targets and these drug molecules, greatly reducing the likelihood of problems such as false positives, false negatives or incorrect binding modes.
Resumen de: MX2025001775A
Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Resumen de: US2024294620A1
Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
Resumen de: WO2024107948A1
A process for determining an extent of a central nervous system (CNS) specific neurological condition in a subject including collecting a biological sample of biofluid from the subject and measuring a quantity of a first biomarker, or metabolite of or mRNA corresponding to, the first biomarker from the sample from a dried spot or through a microfluidic device. The biofluid is capillary blood or saliva, which affords ease of collection advantages that are attractive for field-, hospital-, and home-based environments. The process being useful in the diagnosis, care, and management of brain specific abnormal neurological conditions in general, and in particular, to traumatic brain injury (TBI) and (TBI-induced) Alzheimer's disease (AD) and Alexander disease, in which a GFAP mutation is implicated in white matter deterioration.
Resumen de: TW202438878A
The present disclosure provides a method of manufacturing a biosensor for detecting a biomarker of Alzheimer's disease, comprising steps of depositing an aluminum oxide film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing electrical contacts Cr/Au on the Al2O3/Si substrate by a thermal evaporator to form a source, a drain and a planar gate on the Al2O3/Si substrate; providing a bilayer graphene on the Al2O3/Si substrate by thermal annealing under a vacuum environment; providing a bilayer graphene to a low-damage plasma treatment (LDPT) with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite on the Al2O3/Si substrate; and immobilizing an antibody on a surface of the GO/G layered composite through a reaction between amine groups of the antibody and carboxyl groups of GO of the GO/G layered composites, wherein the antibody is specific for p-tau217 protein.
Resumen de: WO2025188949A1
A sample collection device having a sample container, a solid phase binding material, and a container sealing component is presented. The sample container may have a housing that forms an opening for receiving a sample, and that encloses a space for holding the sample. The solid phase binding material may be disposed within the space enclosed by the housing of the sample container and may be adapted, when the sample contains an analyte, to bind specifically to the analyte. The container sealing component may be removably attachable to the sample container at the opening thereof, and may be adapted, when attached to the sample container, to form a seal around the opening of the sample container.
Resumen de: US2025283897A1
Disclosed is a method for diagnosing Alzheimer's disease based on deep learning and an SAM, and a SERS substrate therefor. According to an embodiment, a deep learning and self-assembled monolayer (SAM)-based Alzheimer's disease diagnosing method performed by a computer device includes preparing a three-dimensional (3D) surface-enhanced Raman scattering (SERS) substrate by continuously stacking nanowire layers arranged in parallel by using a nanotransfer printing technology, forming an SAM on the 3D SERS substrate, and obtaining a Raman signal by applying a metabolite solution on the 3D SERS substrate having the SAM on a surface.
Resumen de: US2025283892A1
The present invention relates to a method for the diagnosis of Alzheimer's Disease, comprising the steps of (i) determining the level of antibodies against YB-1 in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without Alzheimer's Disease, wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative of Alzheimer's Disease in the subject.
Resumen de: AU2023371615A1
Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.
Nº publicación: EP4612502A1 10/09/2025
Solicitante:
NORTH CAROLINA CENTRAL UNIV [US]
UNIV DUKE [US]
North Carolina Central University,
Duke University
Resumen de: WO2024097164A1
Provided are methods of phosho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
BOPI
Sede Electrónica
